| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Whales with a lot of money to spend have taken a noticeably bearish stance on Bristol-Myers Squibb.
Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 50% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $499,586 and 2, calls, for a total amount of $81,470.
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $38.0 to $49.0 for Bristol-Myers Squibb over the last 3 months.
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Bristol-Myers Squibb's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bristol-Myers Squibb's whale trades within a strike price range from $38.0 to $49.0 in the last 30 days.
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BMY | PUT | SWEEP | BEARISH | 12/20/24 | $5.2 | $5.1 | $5.2 | $44.00 | $121.6K | 220 | 0 |
| BMY | PUT | SWEEP | BEARISH | 01/17/25 | $4.6 | $4.5 | $4.6 | $43.00 | $120.0K | 6.8K | 0 |
| BMY | PUT | SWEEP | BEARISH | 11/15/24 | $9.3 | $9.2 | $9.3 | $49.00 | $107.8K | 209 | 0 |
| BMY | PUT | TRADE | BEARISH | 01/17/25 | $3.1 | $2.97 | $3.05 | $40.00 | $91.5K | 20.1K | 0 |
| BMY | CALL | SWEEP | BULLISH | 11/15/24 | $4.35 | $4.2 | $4.3 | $38.00 | $55.4K | 330 | 0 |
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
In light of the recent options history for Bristol-Myers Squibb, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Bristol-Myers Squibb with Benzinga Pro for real-time alerts.
Posted In: BMY
